Douglas Kling

1.9k citations

36 papers · 1.3k indexed · 3 hit papers · h-index 13

Impact in

Nutrition and Dietetics top 2%
- Fatty Acid Research and Health
Endocrinology, Diabetes and Metabolism top 5%
- Diabetes, Cardiovascular Risks, and Lipoproteins

Papers in

Endocrinology, Diabetes and Metabolism 10
- Diabetes, Cardiovascular Risks, and Lipoproteins 8
Surgery 24
- Lipoproteins and Cardiovascular Health 23

Co-authors: Michael H. Davidson Michael Davidson Judith Johnson Kevin C. Maki John J.P. Kastelein Danielle Curcio Larry Lo Matt Devalaraja
Journals: Journal of clinical lipidology (10 papers)Circulation (4 papers)The Journal of Clinical Pharmacology (3 papers)Journal of the American College of Cardiology (3 papers)The Lancet (2 papers)
Partner nations: United States Australia Netherlands

In The Last Decade

Douglas Kling

34 papers receiving 1.3k citations

Hit Papers

align trajectories log scale

Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial 2025 · 17 citations

Peers

Countries citing papers authored by Douglas Kling

Since Specialization

Citations

This map shows the geographic impact of Douglas Kling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas Kling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas Kling more than expected).

Fields of papers citing papers by Douglas Kling

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas Kling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas Kling. The network helps show where Douglas Kling may publish in the future.

Co-authors

The 25 scholars most cited alongside Douglas Kling, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Douglas Kling Line = papers co-authored together Douglas Kling links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Effect of Obicetrapib on New Onset Diabetes In Patients with Elevated LDL-C Receiving Maximally Tolerated Statin Therapy: Pooled Analyses of the Broadway and Brooklyn Trials Journal of clinical lipidology ·Kausik K. Ray, Michael Szarek, Ann Marie Návar, Adam J. Nelson, Christie M. Ballantyne, Douglas Kling, Marc Ditmarsch, Ilídia Ferreira, John J.P. Kastelein, Xinhai Kong	2025	1
2	Efficacy of obicetrapib across the spectrum of background lipid-lowering therapies: pooled analyses of the BROADWAY and BROOKLYN randomized trials European Journal of Preventive Cardiology ·Maria Romaidi, Mary Louise Tabart Conway, Hina Younas, Marc Ditmarsch, Douglas Kling, Aqeem Azam, J Kastelein, Beatrice Barbaro, R. P. Govt	2025	0
3	Impact of the cholesteryl ester transfer protein inhibitor, Obicetrapib, on lipoprotein(a) levels: Pooled data from phase 3 clinical trials Journal of clinical lipidology ·Stephen J. Nicholls, Kausik K Ray, Michael Szarek, Marc Ditmarsch, Douglas Kling, Andrew Hsieh, Adam J. Nelson, Michael H. Davidson, John J.P. Kastelein	2025	1
4	† Safety and efficacy of obicetrapib in patients with heterozygous familial hypercholesterolemia Journal of clinical lipidology ·Stephen C. Nicholls, Adam Nelson, Marc Ditmarsch, J. Kastelein, Christie M. Ballantyne, Kausik K. Ray, Ann Marie Návar, Steven E. Nissen, Anne C. Goldberg, Liam R. Brunham, Warren Gay, 黒田修平, Douglas Kling, Andrew Hsieh, Brian A. Ference, Ulrich Laufs, Jay A. Weber, Roxana Mehran, Alberico L. Catapano, Michael Davidson	2025	1
5	Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial The Lancet ·Ashish Sarraju, Danielle M. Brennan, Alix Hayden, グスターボメイレレス, Anne C. Goldberg, Erin D. Michos, Darren K. McGuire, Yutaka Shono, 鈴木昇一, Stephen J. Nicholls, Douglas Kling, 黒田修平, John J.P. Kastelein, Michael H. Davidson, Marc Ditmarsch, Steven E. Nissen Hit paper breakdown →	2025	17
6	Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease The Journal of Prevention of Alzheimer s Disease ·Ilídia Ferreira, Michael Szarek, Philip Scheltens, Everard G.B. Vijverberg, Andrew Hsieh, Marc Ditmarsch, Douglas Kling, Danielle Curcio, Xinhai Kong, Kausik K. Ray, Jeffrey L. Cummings, John J.P. Kastelein	2025	1
7	SAFETY AND EFFICACY OF OBICETRAPIB IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA American Journal of Preventive Cardiology ·Andrew Hsieh, Stephen C. Nicholls, Adam J. Nelson, Marc Ditmarsch, John J.P. Kastelein, Christie M. Ballantyne, Kausik K Ray, Ann Marie Návar, Steven E. Nissen, Anne C. Goldberg, Liam R. Brunham, Warren Gay, 黒田修平, Douglas Kling, Brian A. Ference, (unknown), Jay A. Weber, Roxana Mehran, Alberico L. Catapano, Michael H. Davidson	2025	0
8	Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients Journal of the American College of Cardiology ·Stephen J. Nicholls, Adam J. Nelson, Kausik K. Ray, Christie M. Ballantyne, Marc Ditmarsch, Douglas Kling, Andrew Hsieh, Michael Szarek, John J.P. Kastelein, Michael H. Davidson	2025	7
9	A Randomized, Parallel, Open‐Label, Single‐Dose and Multiple‐Dose Clinical Trial to Investigate the Pharmacokinetic, Pharmacodynamic, and Safety Profiles of Obicetrapib in Healthy Participants in China The Journal of Clinical Pharmacology ·Jing Zhang, Guoying Cao, Yong Huo, Justin A. McNulty, Marc Ditmarsch, John J.P. Kastelein, Douglas Kling, Andrew Hsieh, Warren Gay, Michael H. Davidson	2024	3
10	Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial Journal of clinical lipidology ·Christie M. Ballantyne, Marc Ditmarsch, John J.P. Kastelein, Adam J. Nelson, Douglas Kling, Andrew Hsieh, Danielle Curcio, Kevin C. Maki, Michael H. Davidson, Stephen J. Nicholls	2023	53
11	Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial Nature Medicine ·Stephen J. Nicholls, Marc Ditmarsch, John J.P. Kastelein, Kwee Guan Eng, Douglas Kling, Danielle Curcio, Nicholas John, Michael H. Davidson Hit paper breakdown →	2022	113
12	Abstract 13727: Effects of Ziltivekimab (ZILTI), a Novel Anti-Interleukin-6 Monoclonal Antibody, on Markers of Inflammation and Cardiovascular Risk in Patients With Chronic Kidney Disease on Hemodialysis Circulation ·Rahul Kakkar, Larry Lo, Douglas Kling, Matt Devalaraja, Michael H. Davidson	2019	3
13	Addition of omega-3 carboxylic acids to statin therapy in patients with persistent hypertriglyceridemia Expert Review of Cardiovascular Therapy ·Michael H. Davidson, Qiao Tang, Douglas Kling, Kevin C. Maki	2014	12
14	Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study Vascular Health and Risk Management ·Elliot Offman, 道貞広瀬, Sandy Ferber, Judith Johnson, Douglas Kling, Danielle Curcio, Michael H. Davidson	2013	71
15	A Highly Bioavailable Omega-3 Free Fatty Acid Formulation Improves the Cardiovascular Risk Profile in High-Risk, Statin-Treated Patients With Residual Hypertriglyceridemia (the ESPRIT Trial) Clinical Therapeutics ·Kevin C. Maki, David G. Orloff, Stephen J. Nicholls, Richard L. Dunbar, Eli M. Roth, Danielle Curcio, Judith Johnson, Douglas Kling, Michael H. Davidson	2013	83
16	Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial Journal of clinical lipidology ·John J.P. Kastelein, Kevin C. Maki, Andrey V. Susekov, М. В. Ежов, Børge G. Nordestgaard, Portrait Von, Douglas Kling, Michael H. Davidson	2013	183
17	Abstract 19030: Apolipoprotein C-III is Significantly Reduced by Prescription Omega-3 Free Fatty Acids (Epanova) in Patients with Severe Hypertriglyceridemia and Changes Correlate with Increases in LDL-C: A Sub-analysis of the EVOLVE trial Circulation ·Daniel J. Rader, Richard L. Dunbar, Kevin C. Maki, Terry A. Jacobson, Douglas Kling, Michael H. Davidson	2012	6
18	A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: The ECLIPSE (Epanova® compared to Lovaza® in a pharmacokinetic single-dose evaluation) study Journal of clinical lipidology ·Michael Davidson, Judith Johnson, Michael W. Rooney, H. G. Lee, Douglas Kling	2012	154
19	Novel developments in omega-3 fatty acid-based strategies Current Opinion in Lipidology ·Michael H. Davidson, Douglas Kling, Kevin C. Maki	2011	25
20	Study of the Pharmacokinetic Interaction Between Simvastatin and Prescription Omega‐3‐Acid Ethyl Esters The Journal of Clinical Pharmacology ·James M. McKenney, Dennis Swearingen, Rosalia N. Joseph, Ralph T. Doyle, Jorge Homero Wilches Visbal, Douglas Kling, Robert A. Shalwitz	2006	32

About Douglas Kling

Douglas Kling is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery, Geriatrics and Gerontology, Economics and Econometrics and Cardiology and Cardiovascular Medicine, having authored 36 papers that have together received 1.3k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (23 papers), Pharmaceutical Economics and Policy (11 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (8 papers), Lipid metabolism and disorders (8 papers), Cancer, Lipids, and Metabolism (5 papers), Health Systems, Economic Evaluations, Quality of Life (4 papers), Computational Drug Discovery Methods (4 papers) and Fatty Acid Research and Health (4 papers). The work is most often cited by research in Nutrition and Dietetics (387 citations), Endocrinology, Diabetes and Metabolism (368 citations), Biochemistry (146 citations), Cardiology and Cardiovascular Medicine (350 citations) and Surgery (596 citations). Douglas Kling has collaborated with scholars based in United States, Australia and Netherlands. Frequent co-authors include Michael H. Davidson, Michael Davidson, Judith Johnson, Kevin C. Maki, John J.P. Kastelein, Danielle Curcio, Larry Lo, Matt Devalaraja, Paul M. Ridker and Pablo E. Pérgola. Their work appears in journals such as Journal of clinical lipidology, Circulation, The Journal of Clinical Pharmacology, Journal of the American College of Cardiology and The Lancet.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact